Abstract: Preparing a cell population rich in cells having a given phenotype depending on their use (e.g., type II collagen-positive nucleus pulposus cells) from a cell population containing Tie2-positive stem/progenitor cells (e.g., nucleus pulposus stem/progenitor cells). The present invention provides culture methods wherein a cell population containing Tie2-positive stem/progenitor cells is cultured (1) while present in a non-digested tissue, (2) in a culture medium containing at least one kind of Tie2 expression enhancer other than growth factors, (3) using cultureware with a culture surface having undergone cell attachment-increasing treatment, or (4) while suppressing formation of spheroid colonies in a culture medium containing an extracellular matrix-degrading agent.

Abstract: An inhibiting or alleviating agent for amyloid beta (A?)-induced damage in hippocampus including an extract from inflamed tissues inoculated with vaccinia virus. Also relates to the use of the extract from inflamed tissues inoculated with vaccinia virus in the preparation of an agent for inhibiting or alleviating A?-induced damage in hippocampus.

Abstract: A Schwann cell differentiation promoting agent, a peripheral nerve regeneration promoting agent, or the like contain an extract from inflamed tissues inoculated with vaccinia virus. The extract from inflamed tissues inoculated with vaccinia virus promotes differentiation of Schwann cells and regeneration of a peripheral nerve. Therefore, a preparation containing the extract from inflamed tissues inoculated with vaccinia virus is useful as a Schwann cell differentiation promoting agent, a peripheral nerve regeneration promoting agent, or the like.

Abstract: The object of the present invention is to provide a test method using a novel administration method of an extract from inflamed tissues inoculated with vaccinia virus or a preparation containing the extract. It has been demonstrated that by sustainedly administering an extract from inflamed tissues inoculated with vaccinia virus or a preparation containing the extract by using a continuous administration device according to the present invention, a comparable effect is exerted at a very low dose compared with conventional administration methods such as oral administration. Therefore, the present invention can provide a test method using animals requiring less burden on a researcher, a treatment of patient at a low dose, and the like.

Abstract: The present invention relates to a pre-processing method for the purpose of formulating a drug substance having non-uniform particle sizes by a manufacturing method having excellent manufacture performance. According to the pre-processing method of the present invention, additives including at least a dispersant are blended in a drug substance having a specific particle size distribution and then the resultant mixture is deagglomerated/sized to disperse and make adhere the additives onto the surfaces of the particles of the drug substance, thereby yielding a powder having a specified particle size distribution. In this manner, a pharmaceutical preparation can be manufactured with excellent manufacture performance, manufacture efficiency, and manufacture cost by a direct compression method, a wet continuous granulation system or the like. Therefore, the pre-processing method is very useful.

Abstract: A method for manufacturing a preparation which contains acetaminophen at a high content, in particular, a miniaturized tablet (conventional tablets, sustained-release tablets, etc.) which have excellent elution properties, preferable hardness and high drug content uniformity, and a premix drug substance of acetaminophen which has improved manufacturability. According to the method in which acetaminophen having a preset particle size is used for manufacturing a preparation, the flowability of acetaminophen can be improved so that secondary agglomeration can be suppressed and manufacturing efficiency can be elevated. Thus, this method is highly useful for manufacturing an acetaminophen preparation having improved administrability, for example, a reduced size.

Abstract: A sustained release sheet that includes a drug for treating nerve injury, wherein the sheet is applied to a nerve injury site, can maintain a high concentration of the drug over a long period, and promotes nerve regeneration without stimulating the nerves, even when the sheet is implanted in the periphery of the nerve injury site. Also provided is a production method for the sheet. This sustained drug release sheet for treating nerve injury is a sheet including a non-woven fabric that is formed from nanofibers each containing a drug such as vitamin B12 and a biocompatible polymer such as a biodegradable aliphatic polyester, and is implanted in the periphery of the nerve injury site to promote nerve regeneration.

Abstract: A preparation which contains acetaminophen at a high content, in particular, a miniaturized tablet (conventional tablets, sustained-release tablets, etc.) which have excellent dissolution properties, preferable hardness and high drug content uniformity and a manufacturing method thereof. Acetaminophen has a preset particle size and is used for manufacturing a preparation, the flowability of acetaminophen can be improved so that secondary agglomeration can be suppressed, manufacturing efficiency can be elevated and the cost for manufacturing is also reduced. Thus, an acetaminophen preparation having improved administrability, for example, a reduced size and a manufacturing method thereof are highly useful.

Abstract: A method for manufacturing a preparation which contains acetaminophen at a high content, in particular, a miniaturized tablet (conventional tablets, sustained-release tablets, etc.) which have excellent elution properties, preferable hardness and high drug content uniformity, and a premix drug substance of acetaminophen which has improved manufacturability. According to the method in which acetaminophen having a preset particle size is used for manufacturing a preparation, the flowability of acetaminophen can be improved so that secondary agglomeration can be suppressed and manufacturing efficiency can be elevated. Thus, this method is highly useful for manufacturing an acetaminophen preparation having improved administrability, for example, a reduced size.

Abstract: A non-woven fabric including fibers including an aliphatic polyester that has at least two maximum values in a molecular weight distribution thereof, wherein the fibers have a fiber diameter falling within the range of 100 to 3000 nm. The non-woven fabric of the present invention has excellent biodegradability.

Abstract: A method of treating a central nervous system disease, the method including administering an agent including a therapeutically effective amount of vitamin B12 to a patient with a central nervous system disease to treat the central nervous system disease. This disclosure also relates to a method of promoting M2 macrophage/microglia induction, inhibiting M1 macrophage/microglia induction, and/or reducing the ratio of M1 macrophage/microglia to M2 macrophage/microglia in a patient in need thereof, the method including administering an agent including a therapeutically effective amount of vitamin B12 to the patient to promote M2 macrophage/microglia induction, inhibit M1 macrophage/microglia induction, and/or reduce the ratio of M1 macrophage/microglia to M2 macrophage/microglia. This disclosure also relates to a pharmaceutical product including vitamin B12.

Abstract: A low-molecular-weight compound (IL-17 activity inhibitor) having an IL-17 activity-inhibiting ability.

Abstract: Provided are an expression inhibitor of an inflammation promoting factor based on the discovery of a new factor influencing the expression amount/level of an inflammation promoting factor, and a development tool therefor. Provided are also a diagnostic agent and a diagnosis method for immune diseases, inflammatory diseases, painful conditions and similar. More specifically provided are: an expression inhibitor of an inflammation promoting factor containing at least one kind of inhibitor selected from the group consisting of RBMS2 expression inhibitor and RBMS2 function inhibitor; a screening method using as an indicator the expression or the function of RBMS2; an expression cassette useful for said method; as well as a diagnostic agent containing a product detection agent for RBMS2 gene expression and disease detection method using as an indicator RBMS2 gene expression amount/level.

Abstract: Provided are an expression inhibitor of a cancer promoting factor based on the discovery of a new factor influencing the expression amount/level of a cancer romoting factor, and a development tool therefor. Provided are also a diagnostic agent and a diagnosis method for cancer. More specifically provided are: an expression inhibitor of a cancer promoting factor containing at least one kind of inhibitor selected from the group consisting of RBMS expression inhibitor and RBMS function inhibitor; a screening method using as an indicator the expression or the function of RBMS; an expression cassette useful for said method; as well as a diagnostic agent containing a product detection agent for RBMS gene expression and cancer detection method using as an indicator RBMS gene expression amount/level.

Abstract: A lipocalin-type prostaglandin D2 synthase (L-PGDS) production promoting agent, more specifically an L-PGDS production promoting agent in pericytes or ischemia-induced multipotent stem cells (iSCs) dedifferentiated from pericytes. A substance having an L-PGDS production promoting action is contained in an extract from inflamed tissues inoculated with vaccinia virus. An L-PGDS production promoting agent is highly useful as a prophylactic, therapeutic or relapse prophylactic agent for a disease in which the effect by promotion of L-PGDS expression is expected to be effective, including a cerebrovascular disorder such as cerebral infarction, dementia such as Alzheimer's disease, or a sleep disorder.

Abstract: The purpose of the present invention is to provide a medicament which is useful for prevention or treatment of muscle injury. The present invention relates to a novel medical use of an extract from inflamed tissues inoculated with vaccinia virus, and more particularly, it relates to a preventing or therapeutic agent for muscle injury containing the extract as an active ingredient. The preventing or therapeutic agent for muscle injury of the present invention containing the extract as an active ingredient is extremely useful as a highly effective and highly safe medicament.

Abstract: An object of the present invention is to provide a protective method for liver comprising the administration of an extract from inflamed tissues inoculated with vaccinia virus to a patient who needs the treatment and to provide a liver protective agent, etc. where such an extract is an active ingredient. In the present invention, it has been recognized that, in hepatocytes, activation of NF-B, expression of NF-B target genes, activation of JNK, apoptosis and fat accumulation can be inhibited or suppressed. The agent containing the extract as an active ingredient is a drug exhibiting less adverse action and high safety. Accordingly, the present invention provides very useful protective method for liver and liver protecting agent.

Abstract: An inhibiting or alleviating agent for amyloid beta (A?)-induced damage in hippocampus including an extract from inflamed tissues inoculated with vaccinia virus. Also relates to the use of the extract from inflamed tissues inoculated with vaccinia virus in the preparation of an agent for inhibiting or alleviating A?-induced damage in hippocampus.

Abstract: A carcinogenesis inhibitor having no side effect and having an excellent effect by oral administration. A carcinogenesis inhibitor containing a hydantoin derivative or a pharmaceutically acceptable salt thereof as an active ingredient shows an inhibiting action for polyp formation and for cell proliferation, and has no side effect and highly safe whereby it is very highly useful as a pharmaceutical agent and a food such as supplement which prevent the occurrence and progress of cancer, inhibits the recurrence and metastasis of cancer and further achieves the therapeutic effect.

Abstract: An agent for promoting migration of pluripotent stem cells containing an extract from inflamed tissues inoculated with vaccinia virus. An extract from inflamed tissues inoculated with vaccinia virus promotes migration of Muse cells. Thus, the agent for promoting migration of pluripotent stem cells for various diseases to which migration of pluripotent stem cells may have an advantageous effect.